Literature DB >> 31041948

Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.

Zhan Zhou1, Xiaojuan Chen, Ying Fu, Ye Zhang, Shuyan Dai, Jun Li, Lin Chen, Guangyu Xu, Zhuchu Chen, Yongheng Chen.   

Abstract

Biochemical and structural studies provide information on the mode of action of FGF401 as a selective, reversible covalent inhibitor of FGFR4. Kinase and proliferation assays reveal that FGF401 has the ability to overcome gatekeeper mutations in FGFR4.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31041948     DOI： 10.1039/c9cc02052g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  6 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

Authors:  Stephen L Chan; Martin Schuler; Yoon-Koo Kang; Chia-Jui Yen; Julien Edeline; Su Pin Choo; Chia-Chi Lin; Takuji Okusaka; Karl-Heinz Weiss; Teresa Macarulla; Stéphane Cattan; Jean-Frederic Blanc; Kyung-Hun Lee; Michela Maur; Shubham Pant; Masatoshi Kudo; Eric Assenat; Andrew X Zhu; Thomas Yau; Ho Yeong Lim; Jordi Bruix; Andreas Geier; Carmen Guillén-Ponce; Angelica Fasolo; Richard S Finn; Jia Fan; Arndt Vogel; Shukui Qin; Markus Riester; Vasiliki Katsanou; Monica Chaudhari; Tomoyuki Kakizume; Yi Gu; Diana Graus Porta; Andrea Myers; Jean-Pierre Delord
Journal:  J Exp Clin Cancer Res       Date:  2022-06-02

3.  N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.

Authors:  Yutian Zou; Shaoquan Zheng; Xinhua Xie; Feng Ye; Xiaoqian Hu; Zhi Tian; Shu-Mei Yan; Lu Yang; Yanan Kong; Yuhui Tang; Wenwen Tian; Jindong Xie; Xinpei Deng; Yan Zeng; Zhe-Sheng Chen; Hailin Tang; Xiaoming Xie
Journal:  Nat Commun       Date:  2022-05-13       Impact factor: 17.694

Review 4.  Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors.

Authors:  Shuyan Dai; Zhan Zhou; Zhuchu Chen; Guangyu Xu; Yongheng Chen
Journal:  Cells       Date:  2019-06-18       Impact factor: 6.600

Review 5.  FGFR-TKI resistance in cancer: current status and perspectives.

Authors:  Sitong Yue; Yukun Li; Xiaojuan Chen; Juan Wang; Meixiang Li; Yongheng Chen; Daichao Wu
Journal:  J Hematol Oncol       Date:  2021-02-10       Impact factor: 17.388

Review 6.  Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.

Authors:  Yanan Liu; Meng Cao; Yuepiao Cai; Xiaokun Li; Chengguang Zhao; Ri Cui
Journal:  Front Cell Dev Biol       Date:  2020-02-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.